A recent study suggested that elevated plasma MPO in patients with CAD were directly related to the severity of CAD and the risk of developing MACE, and that reducing MPO has important clinical implications for improving prognosis (Cheng et al., 2020). This evidence concerns the gene MPO and coronary artery disorder.